Cancer Therapy News and Research

RSS

New polysaccharide may help combat multidrug resistance in cancer

In a recent study published in the Journal of Biological Chemistry, scientists report that a molecule previously thought to play a purely structural and inert role in cells is actually involved in multidrug resistance in cancer.

22 May 2005

New drug combination prevents breast cancer growth pre-surgery

A new type of drug originally developed for lung cancer can reduce the size of breast cancer tumours when taken in combination with other drugs.

17 May 2005

Vitamin D, taxotere combination promising for advanced prostate cancer

Results of a new study strongly suggest that DN-101, a new high-dose calcitriol pill designed specifically as a cancer therapy, given in combination with docetaxel (Taxotere) extends the lives of men with advanced prostate cancer.

17 May 2005

Antibody combined with cancer drug shows promise against breast tumors

An antibody that targets the blood vessels nourishing tumors significantly reduced breast cancer formation and growth in mice when combined with a current cancer drug, according to researchers at UT Southwestern Medical Center.

16 May 2005

Tarvacin equivalent plus Docetaxel inhibits breast tumor growth by 93%

Peregrine Pharmaceuticals, Inc., today announced that a research article titled "A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice" was published in the May 15 issue of Cancer Research.

16 May 2005

Genetic biomarker that may improve quality of life during treatment for colorectal cancer

A Mayo Clinic-led study has revealed a genetic biomarker that can predict which patients are most likely to experience unwanted side effects from one of the most commonly used and highly effective chemotherapy regimens designed to treat colorectal cancer.

16 May 2005

Zometa reduces bone loss in patients receiving breast cancer treatment

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence).

16 May 2005

Tamoxifen study counters hopes that drug might protect the heart

Despite previous studies hinting at tamoxifen's potential benefit for breast cancer survivors' heart health, California researchers have found that the breast cancer drug does not decrease survivors' risk of heart attack.

15 May 2005

Research findings help predict risk of blood clots in women receiving tamoxifen therapy for breast cancer

New research findings may help physicians determine which women have an increased risk of blood clots when taking tamoxifen for the management of breast cancer, a team led by Dana-Farber Cancer Institute investigators will report at the American Society of Clinical Oncology's annual meeting.

15 May 2005

Black cohosh does not reduce hot flashes in women

Mayo Clinic researchers, working with North Central Cancer Treatment Group (NCCTG) investigators, will present new study findings about treatments to reduce hot flashes in women. The research will be outlined during the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting, May 13-17 in Orlando, Fla.

15 May 2005

Doctors and patients think differently about clinical trials

A survey of patients and physicians regarding clinical trials shows that doctors don't recognize the importance of side effects as a barrier for their patients in deciding about whether to undergo experimental therapy.

15 May 2005

Counting number of endothelial cells in blood may predict cancer treatment's effectiveness

Counting the amount of a type of normal cell circulating in the blood of people with cancer could predict whether a tumor progresses or responds to therapy, a new study led by the University of Michigan Comprehensive Cancer Center has found. The finding could give doctors an early indication of whether a treatment will be successful, sparing patients months of an ineffective therapy.

15 May 2005

First advance in pancreatic cancer treatment in a decade offers new hope

The first advance in pancreatic cancer treatment in a decade has been achieved by researchers in a Canadian-led study, and at last gives some encouragement to scientists and invigorates a field that has experienced more than its share of disheartening failures.

15 May 2005

New laser technology for more precise cancer treatments

Tom Cowan’s team is thinking smaller, but with big impact. Particle accelerators are a key research tool in a high energy physicist’s arsenal, but they take up a lot of space - miles and miles of it. But at the University of Nevada, Reno, smaller is better.

10 May 2005

Research offers new molecular approaches to therapies for the most deadly cancers

Researchers at Wake Forest University Baptist Medical Center have found promising new molecular targets and treatment approaches for some of the most malignant brain tumors.

10 May 2005

Cytogen Corporation and Dowpharma collaborate to create a targeted oncology product designed to treat prostate and other cancers

Under the agreement, Dowpharma's proprietary MeO-DOTA bifunctional chelant technology will be used to radiolabel Cytogen's prostate-specific membrane antigen (PSMA) antibody with a therapeutic radionuclide. PSMA is a protein highly expressed on the surface of prostate cancer cells and the neovasculature of many solid tumors.

10 May 2005

Researchers develop promising new gene network analysis method

Compared with a long-used linear model, a correlation-based statistical method is a more reliable way to map complex gene interactions and pinpoint genes that may be potential cancer treatment targets, according to new Brown University research.

8 May 2005

Promising new molecular targets and treatment approaches for some of the most malignant brain tumors

The first study identified a protein that seems to control the malignant features of brain tumor cells, suggesting a new treatment target for anti-cancer drugs. Researchers found that a little-known protein called Fra-1 was effective in controlling vascular endothelial growth factor D, a factor that promotes the growth of new blood vessels in most malignant brain tumors.

8 May 2005

Fusing physics with medicine to fight cancer

Everyone’s lives are touched by cancer - it is a disease that affects 1 in 3 of us throughout our lifetime. Future developments that lead to earlier diagnosis and more effective therapy lie in further successful collaboration between high energy physicists and the healthcare industry.

2 May 2005

Blocking the COX-1 enzyme might be the answer in ovarian cancer treatment

Researchers at Vanderbilt University Medical Center in a new report say that blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer.

2 May 2005